Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
40.78
-1.14 (-2.72%)
Nov 3, 2025, 1:20 PM EST - Market open
Xenon Pharmaceuticals Revenue
Xenon Pharmaceuticals had revenue of $7.50M in the twelve months ending June 30, 2025.
Revenue (ttm)
$7.50M
Revenue Growth
n/a
P/S Ratio
419.04
Revenue / Employee
$22,936
Employees
327
Market Cap
3.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 9.43M | -9.00M | -48.83% |
| Dec 31, 2021 | 18.44M | -13.73M | -42.68% |
| Dec 31, 2020 | 32.17M | 25.34M | 371.02% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
XENE News
- 7 days ago - Xenon to Report Q3 2025 Financial Results on November 3, 2025 - GlobeNewsWire
- 18 days ago - Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer - GlobeNewsWire
- 26 days ago - Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 27 days ago - Xenon Pharmaceuticals Inc. - Special Call - Seeking Alpha
- 5 weeks ago - Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain - GlobeNewsWire
- 2 months ago - Xenon Pharmaceuticals: Pushing Azetukalner Towards Finish Line With Phase 3 2026 Data Release - Seeking Alpha
- 2 months ago - Xenon Pharmaceuticals Inc. (XENE) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Xenon Reports Second Quarter 2025 Financial Results & Business Update - GlobeNewsWire